Assetmark Inc. Boosts Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Assetmark Inc. grew its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 11.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 44,185 shares of the company’s stock after buying an additional 4,481 shares during the period. Assetmark Inc.’s holdings in IDEAYA Biosciences were worth $1,400,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in IDEAYA Biosciences in the first quarter worth $101,000. Oppenheimer & Co. Inc. acquired a new stake in IDEAYA Biosciences in the first quarter worth about $217,000. Swiss National Bank grew its stake in shares of IDEAYA Biosciences by 30.9% during the first quarter. Swiss National Bank now owns 111,400 shares of the company’s stock worth $4,888,000 after acquiring an additional 26,300 shares during the last quarter. ProShare Advisors LLC increased its holdings in shares of IDEAYA Biosciences by 21.1% during the first quarter. ProShare Advisors LLC now owns 17,047 shares of the company’s stock valued at $748,000 after acquiring an additional 2,966 shares in the last quarter. Finally, Entropy Technologies LP acquired a new stake in IDEAYA Biosciences in the 1st quarter worth approximately $679,000. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on IDYA shares. Leerink Partners cut shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $41.00 to $27.00 in a report on Tuesday, November 5th. Lifesci Capital raised IDEAYA Biosciences to a “strong-buy” rating in a research report on Monday, July 29th. UBS Group assumed coverage on IDEAYA Biosciences in a research note on Thursday, October 24th. They issued a “buy” rating and a $50.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $53.91.

IDEAYA Biosciences Stock Performance

IDYA stock opened at $29.47 on Friday. IDEAYA Biosciences, Inc. has a one year low of $27.52 and a one year high of $47.74. The firm’s fifty day moving average is $31.77 and its 200 day moving average is $36.51. The firm has a market cap of $2.55 billion, a PE ratio of -13.09 and a beta of 0.86.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same period last year, the firm earned ($0.46) EPS. Research analysts predict that IDEAYA Biosciences, Inc. will post -2.46 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.